Immunocompromised patients with metastatic cutaneous nodal squamous cell carcinoma of the head and neck: Poor outcome unrelated to the index lesion
Background Immunocompromised patients with metastatic cutaneous nodal head and neck squamous cell carcinoma (HNSCC) have worse outcomes compared to the immunocompetent. The purpose of this study was to investigate the characteristics of the primary cutaneous squamous cell carcinoma (SCC), nodal path...
Gespeichert in:
| Veröffentlicht in: | Head & neck 2018-05, Vol.40 (5), p.985-992 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 992 |
|---|---|
| container_issue | 5 |
| container_start_page | 985 |
| container_title | Head & neck |
| container_volume | 40 |
| creator | Lam, Johnson K. S. Sundaresan, Puma Gebski, Val Veness, Michael J. |
| description | Background
Immunocompromised patients with metastatic cutaneous nodal head and neck squamous cell carcinoma (HNSCC) have worse outcomes compared to the immunocompetent. The purpose of this study was to investigate the characteristics of the primary cutaneous squamous cell carcinoma (SCC), nodal pathology, and outcome between these 2 groups.
Methods
Analysis of a prospective database was performed. A 2:1 pooled analysis selected 46 immunocompetent patients matched with 23 immunocompromised patients. Overall survival (OS) and relapse‐free survival (RFS) were calculated using the Kaplan‐Meier method.
Results
No significant difference was found in the primary tumor characteristics between the 2 groups. In the immunocompromised group, RFS (hazard ratio [HR] 2.70; P = .01) and OS (HR 2.32; P = .04) were significantly worse. Extracapsular spread was present in 100% of the immunocompromised patients.
Conclusion
No significant difference was identified in the primary cutaneous SCC between the immunocompetent and immunocompromised patients. Immunosuppression predicted worse outcome. |
| doi_str_mv | 10.1002/hed.25069 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1990488800</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1990488800</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3539-99fc8bef9d17dc39493e072c439f7167ad391edb40d8ccaf22dd5d24959852923</originalsourceid><addsrcrecordid>eNp1kctuFDEQRS0EImFgwQ8gS2xg0Um17X6YXRQCiRQJFrC2PHa1pkPbnvihkO_gh_Gkkw0Sq3KVjm751iXkbQsnLQA73aE9YR308hk5bkEODXAxPD-8BW84DOKIvErpBgB4L9hLcsQk74H17Jj8uXKu-GCC28fg5oSW7nWe0edE7-a8ow6zTrmODDUla4-hJOqD1QtNt0W7Q2twWajR0cw-OE3DRPMO6Q61pdpb6tH8-kS_hxBpKLmuQlp8xEXnui2HB3j2Fn_TBdMc_GvyYtJLwjePdUN-frn4cX7ZXH_7enV-dt0Y3nHZSDmZcYuTtO1gDZdCcoSBGcHlNLT9oC2XLdqtADsaoyfGrO0sE7KTY8ck4xvyYdWt1m8LpqzqAQ5eVpeqlRLEOI71bBvy_h_0JpTo6-8UAzaOHAR0lfq4UiaGlCJOah9np-O9akEdklI1KfWQVGXfPSqWravTJ_IpmgqcrsDdvOD9_5XU5cXnVfIv1pKfLQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2028830405</pqid></control><display><type>article</type><title>Immunocompromised patients with metastatic cutaneous nodal squamous cell carcinoma of the head and neck: Poor outcome unrelated to the index lesion</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Lam, Johnson K. S. ; Sundaresan, Puma ; Gebski, Val ; Veness, Michael J.</creator><creatorcontrib>Lam, Johnson K. S. ; Sundaresan, Puma ; Gebski, Val ; Veness, Michael J.</creatorcontrib><description>Background
Immunocompromised patients with metastatic cutaneous nodal head and neck squamous cell carcinoma (HNSCC) have worse outcomes compared to the immunocompetent. The purpose of this study was to investigate the characteristics of the primary cutaneous squamous cell carcinoma (SCC), nodal pathology, and outcome between these 2 groups.
Methods
Analysis of a prospective database was performed. A 2:1 pooled analysis selected 46 immunocompetent patients matched with 23 immunocompromised patients. Overall survival (OS) and relapse‐free survival (RFS) were calculated using the Kaplan‐Meier method.
Results
No significant difference was found in the primary tumor characteristics between the 2 groups. In the immunocompromised group, RFS (hazard ratio [HR] 2.70; P = .01) and OS (HR 2.32; P = .04) were significantly worse. Extracapsular spread was present in 100% of the immunocompromised patients.
Conclusion
No significant difference was identified in the primary cutaneous SCC between the immunocompetent and immunocompromised patients. Immunosuppression predicted worse outcome.</description><identifier>ISSN: 1043-3074</identifier><identifier>EISSN: 1097-0347</identifier><identifier>DOI: 10.1002/hed.25069</identifier><identifier>PMID: 29360262</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Carcinoma, Squamous Cell - immunology ; Carcinoma, Squamous Cell - mortality ; Carcinoma, Squamous Cell - secondary ; Case-Control Studies ; cutaneous squamous cell carcinoma ; Disease-Free Survival ; Female ; Head & neck cancer ; head and neck ; Head and Neck Neoplasms - immunology ; Head and Neck Neoplasms - mortality ; Head and Neck Neoplasms - secondary ; Humans ; immunocompromised ; Immunocompromised Host ; Immunocompromised hosts ; Immunosuppression ; Male ; Metastases ; Metastasis ; metastatic ; Middle Aged ; Neck ; nodal metastases ; Skin cancer ; Skin Neoplasms - immunology ; Skin Neoplasms - mortality ; Skin Neoplasms - pathology ; Squamous cell carcinoma ; Survival Rate ; Young Adult</subject><ispartof>Head & neck, 2018-05, Vol.40 (5), p.985-992</ispartof><rights>2018 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3539-99fc8bef9d17dc39493e072c439f7167ad391edb40d8ccaf22dd5d24959852923</citedby><cites>FETCH-LOGICAL-c3539-99fc8bef9d17dc39493e072c439f7167ad391edb40d8ccaf22dd5d24959852923</cites><orcidid>0000-0001-6933-4867</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhed.25069$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhed.25069$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29360262$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lam, Johnson K. S.</creatorcontrib><creatorcontrib>Sundaresan, Puma</creatorcontrib><creatorcontrib>Gebski, Val</creatorcontrib><creatorcontrib>Veness, Michael J.</creatorcontrib><title>Immunocompromised patients with metastatic cutaneous nodal squamous cell carcinoma of the head and neck: Poor outcome unrelated to the index lesion</title><title>Head & neck</title><addtitle>Head Neck</addtitle><description>Background
Immunocompromised patients with metastatic cutaneous nodal head and neck squamous cell carcinoma (HNSCC) have worse outcomes compared to the immunocompetent. The purpose of this study was to investigate the characteristics of the primary cutaneous squamous cell carcinoma (SCC), nodal pathology, and outcome between these 2 groups.
Methods
Analysis of a prospective database was performed. A 2:1 pooled analysis selected 46 immunocompetent patients matched with 23 immunocompromised patients. Overall survival (OS) and relapse‐free survival (RFS) were calculated using the Kaplan‐Meier method.
Results
No significant difference was found in the primary tumor characteristics between the 2 groups. In the immunocompromised group, RFS (hazard ratio [HR] 2.70; P = .01) and OS (HR 2.32; P = .04) were significantly worse. Extracapsular spread was present in 100% of the immunocompromised patients.
Conclusion
No significant difference was identified in the primary cutaneous SCC between the immunocompetent and immunocompromised patients. Immunosuppression predicted worse outcome.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Carcinoma, Squamous Cell - immunology</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Carcinoma, Squamous Cell - secondary</subject><subject>Case-Control Studies</subject><subject>cutaneous squamous cell carcinoma</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Head & neck cancer</subject><subject>head and neck</subject><subject>Head and Neck Neoplasms - immunology</subject><subject>Head and Neck Neoplasms - mortality</subject><subject>Head and Neck Neoplasms - secondary</subject><subject>Humans</subject><subject>immunocompromised</subject><subject>Immunocompromised Host</subject><subject>Immunocompromised hosts</subject><subject>Immunosuppression</subject><subject>Male</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>metastatic</subject><subject>Middle Aged</subject><subject>Neck</subject><subject>nodal metastases</subject><subject>Skin cancer</subject><subject>Skin Neoplasms - immunology</subject><subject>Skin Neoplasms - mortality</subject><subject>Skin Neoplasms - pathology</subject><subject>Squamous cell carcinoma</subject><subject>Survival Rate</subject><subject>Young Adult</subject><issn>1043-3074</issn><issn>1097-0347</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctuFDEQRS0EImFgwQ8gS2xg0Um17X6YXRQCiRQJFrC2PHa1pkPbnvihkO_gh_Gkkw0Sq3KVjm751iXkbQsnLQA73aE9YR308hk5bkEODXAxPD-8BW84DOKIvErpBgB4L9hLcsQk74H17Jj8uXKu-GCC28fg5oSW7nWe0edE7-a8ow6zTrmODDUla4-hJOqD1QtNt0W7Q2twWajR0cw-OE3DRPMO6Q61pdpb6tH8-kS_hxBpKLmuQlp8xEXnui2HB3j2Fn_TBdMc_GvyYtJLwjePdUN-frn4cX7ZXH_7enV-dt0Y3nHZSDmZcYuTtO1gDZdCcoSBGcHlNLT9oC2XLdqtADsaoyfGrO0sE7KTY8ck4xvyYdWt1m8LpqzqAQ5eVpeqlRLEOI71bBvy_h_0JpTo6-8UAzaOHAR0lfq4UiaGlCJOah9np-O9akEdklI1KfWQVGXfPSqWravTJ_IpmgqcrsDdvOD9_5XU5cXnVfIv1pKfLQ</recordid><startdate>201805</startdate><enddate>201805</enddate><creator>Lam, Johnson K. S.</creator><creator>Sundaresan, Puma</creator><creator>Gebski, Val</creator><creator>Veness, Michael J.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6933-4867</orcidid></search><sort><creationdate>201805</creationdate><title>Immunocompromised patients with metastatic cutaneous nodal squamous cell carcinoma of the head and neck: Poor outcome unrelated to the index lesion</title><author>Lam, Johnson K. S. ; Sundaresan, Puma ; Gebski, Val ; Veness, Michael J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3539-99fc8bef9d17dc39493e072c439f7167ad391edb40d8ccaf22dd5d24959852923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Carcinoma, Squamous Cell - immunology</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Carcinoma, Squamous Cell - secondary</topic><topic>Case-Control Studies</topic><topic>cutaneous squamous cell carcinoma</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Head & neck cancer</topic><topic>head and neck</topic><topic>Head and Neck Neoplasms - immunology</topic><topic>Head and Neck Neoplasms - mortality</topic><topic>Head and Neck Neoplasms - secondary</topic><topic>Humans</topic><topic>immunocompromised</topic><topic>Immunocompromised Host</topic><topic>Immunocompromised hosts</topic><topic>Immunosuppression</topic><topic>Male</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>metastatic</topic><topic>Middle Aged</topic><topic>Neck</topic><topic>nodal metastases</topic><topic>Skin cancer</topic><topic>Skin Neoplasms - immunology</topic><topic>Skin Neoplasms - mortality</topic><topic>Skin Neoplasms - pathology</topic><topic>Squamous cell carcinoma</topic><topic>Survival Rate</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lam, Johnson K. S.</creatorcontrib><creatorcontrib>Sundaresan, Puma</creatorcontrib><creatorcontrib>Gebski, Val</creatorcontrib><creatorcontrib>Veness, Michael J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Head & neck</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lam, Johnson K. S.</au><au>Sundaresan, Puma</au><au>Gebski, Val</au><au>Veness, Michael J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunocompromised patients with metastatic cutaneous nodal squamous cell carcinoma of the head and neck: Poor outcome unrelated to the index lesion</atitle><jtitle>Head & neck</jtitle><addtitle>Head Neck</addtitle><date>2018-05</date><risdate>2018</risdate><volume>40</volume><issue>5</issue><spage>985</spage><epage>992</epage><pages>985-992</pages><issn>1043-3074</issn><eissn>1097-0347</eissn><abstract>Background
Immunocompromised patients with metastatic cutaneous nodal head and neck squamous cell carcinoma (HNSCC) have worse outcomes compared to the immunocompetent. The purpose of this study was to investigate the characteristics of the primary cutaneous squamous cell carcinoma (SCC), nodal pathology, and outcome between these 2 groups.
Methods
Analysis of a prospective database was performed. A 2:1 pooled analysis selected 46 immunocompetent patients matched with 23 immunocompromised patients. Overall survival (OS) and relapse‐free survival (RFS) were calculated using the Kaplan‐Meier method.
Results
No significant difference was found in the primary tumor characteristics between the 2 groups. In the immunocompromised group, RFS (hazard ratio [HR] 2.70; P = .01) and OS (HR 2.32; P = .04) were significantly worse. Extracapsular spread was present in 100% of the immunocompromised patients.
Conclusion
No significant difference was identified in the primary cutaneous SCC between the immunocompetent and immunocompromised patients. Immunosuppression predicted worse outcome.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29360262</pmid><doi>10.1002/hed.25069</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-6933-4867</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-3074 |
| ispartof | Head & neck, 2018-05, Vol.40 (5), p.985-992 |
| issn | 1043-3074 1097-0347 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1990488800 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adolescent Adult Aged Aged, 80 and over Carcinoma, Squamous Cell - immunology Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - secondary Case-Control Studies cutaneous squamous cell carcinoma Disease-Free Survival Female Head & neck cancer head and neck Head and Neck Neoplasms - immunology Head and Neck Neoplasms - mortality Head and Neck Neoplasms - secondary Humans immunocompromised Immunocompromised Host Immunocompromised hosts Immunosuppression Male Metastases Metastasis metastatic Middle Aged Neck nodal metastases Skin cancer Skin Neoplasms - immunology Skin Neoplasms - mortality Skin Neoplasms - pathology Squamous cell carcinoma Survival Rate Young Adult |
| title | Immunocompromised patients with metastatic cutaneous nodal squamous cell carcinoma of the head and neck: Poor outcome unrelated to the index lesion |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T07%3A30%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunocompromised%20patients%20with%20metastatic%20cutaneous%20nodal%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck:%20Poor%20outcome%20unrelated%20to%20the%20index%20lesion&rft.jtitle=Head%20&%20neck&rft.au=Lam,%20Johnson%20K.%20S.&rft.date=2018-05&rft.volume=40&rft.issue=5&rft.spage=985&rft.epage=992&rft.pages=985-992&rft.issn=1043-3074&rft.eissn=1097-0347&rft_id=info:doi/10.1002/hed.25069&rft_dat=%3Cproquest_cross%3E1990488800%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2028830405&rft_id=info:pmid/29360262&rfr_iscdi=true |